For millions of older adults who dutifully undergo repeat colonoscopies after a prior polyp finding, a growing body of evidence is challenging whether continued surveillance delivers meaningful benefit past age 75 — or whether it diverts clinical attention from more pressing threats to longevity.
A correspondence published in JAMA Network raises two substantive interpretive concerns about a landmark dataset showing that, among adults 75 and older — even those with a documented prior adenoma — deaths from non-colorectal causes substantially outpace colorectal cancer mortality. The correspondence authors do not dispute the core numbers but argue that the clinical framing of these results matters enormously for how physicians and patients approach surveillance decisions. Their points center on how competing mortality risks should influence risk stratification and whether existing surveillance guidelines adequately account for the reduced benefit-to-burden ratio in this age cohort. The letter stops short of disclosing the specific methodological critiques, providing strong reason to consult the original.
This exchange reflects a broader reckoning in gastroenterology and geriatrics: colonoscopy carries real procedural risks — perforation, bleeding, and cardiopulmonary complications — that escalate with age, yet surveillance intervals for older adults with adenoma history have historically been set with younger populations in mind. The United States Preventive Services Task Force already recommends against routine screening initiation after age 75, but post-polypectomy surveillance is governed by separate adenoma-specific guidelines that have lagged in incorporating competing-risk frameworks. This correspondence reinforces that the field is actively reconsidering those norms. For population-level health planning, the implication is significant: reducing low-yield surveillance in older adults could redirect endoscopic capacity toward higher-yield younger or unscreened populations. This is incremental but clinically meaningful evidence supporting individualized, age-conscious decision-making in colorectal cancer follow-up.